Cargando…

Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis

Nonalcoholic fatty liver disease (NAFLD) is associated with impaired hepatic actions of glucagon and insulin. Glucagon and amino acids are linked in an endocrine feedback circuit, the liver–alpha cell axis, that may be disrupted by NAFLD. We investigated how NAFLD severity affects glucagon and insul...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Julie Steen, Rygg, Marte Opseth, Kristiansen, Viggo Bjerregaard, Olsen, Beth Hærstedt, Serizawa, Reza Rafiolsadat, Holst, Jens Juul, Madsbad, Sten, Gluud, Lise Lotte, Bendtsen, Flemming, Wewer Albrechtsen, Nicolai Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603528/
https://www.ncbi.nlm.nih.gov/pubmed/33163832
http://dx.doi.org/10.1002/hep4.1562
_version_ 1783603942418022400
author Pedersen, Julie Steen
Rygg, Marte Opseth
Kristiansen, Viggo Bjerregaard
Olsen, Beth Hærstedt
Serizawa, Reza Rafiolsadat
Holst, Jens Juul
Madsbad, Sten
Gluud, Lise Lotte
Bendtsen, Flemming
Wewer Albrechtsen, Nicolai Jacob
author_facet Pedersen, Julie Steen
Rygg, Marte Opseth
Kristiansen, Viggo Bjerregaard
Olsen, Beth Hærstedt
Serizawa, Reza Rafiolsadat
Holst, Jens Juul
Madsbad, Sten
Gluud, Lise Lotte
Bendtsen, Flemming
Wewer Albrechtsen, Nicolai Jacob
author_sort Pedersen, Julie Steen
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) is associated with impaired hepatic actions of glucagon and insulin. Glucagon and amino acids are linked in an endocrine feedback circuit, the liver–alpha cell axis, that may be disrupted by NAFLD. We investigated how NAFLD severity affects glucagon and insulin resistance in individuals with obesity and whether bariatric surgery improves these parameters. Plasma and liver biopsies from 33 individuals with obesity (collectively, OBE) were obtained before and 12 months after bariatric surgery (Roux‐en‐Y gastric bypass [RYGB] or sleeve gastrectomy [SG]). Nine healthy control individuals (collectively, CON) undergoing cholecystectomy were used as a comparison group. The NAFLD activity score (NAS) was used to subdivide study participants into the following groups: OBE‐no steatosis, OBE+steatosis, and nonalcoholic steatohepatitis (NASH) and/or grade 2 fibrosis (Fib) (OBE‐NASH‐Fib). Measurements of amino acids by targeted metabolomics and glucagon were performed. Glucagon, amino acids (P < 0.05), and the glucagon‐alanine index, a validated surrogate marker of glucagon resistance, were increased in OBE by 60%, 56%, and 61%, respectively, when compared with CON but irrespective of NAFLD severity. In contrast, markers of hepatic insulin resistance increased concomitantly with NAS. Hyperglucagonemia resolved in OBE‐no steatosis and OBE+steatosis but not in OBE‐NASH‐Fib (median, 7.0; interquartile range, 5.0‐9.8 pmol/L), regardless of improvement in insulin resistance and NAS. The type of surgery that participants underwent had no effect on metabolic outcomes. Conclusion: Glucagon resistance to amino acid metabolism exists in individuals with NAFLD independent of NAS severity. Patients with NASH showed persistent hyperglucagonemia 12 months after bariatric surgery, indicating that a disrupted liver–alpha cell may remain in NAFLD despite major improvement in liver histology.
format Online
Article
Text
id pubmed-7603528
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76035282020-11-05 Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis Pedersen, Julie Steen Rygg, Marte Opseth Kristiansen, Viggo Bjerregaard Olsen, Beth Hærstedt Serizawa, Reza Rafiolsadat Holst, Jens Juul Madsbad, Sten Gluud, Lise Lotte Bendtsen, Flemming Wewer Albrechtsen, Nicolai Jacob Hepatol Commun Original Articles Nonalcoholic fatty liver disease (NAFLD) is associated with impaired hepatic actions of glucagon and insulin. Glucagon and amino acids are linked in an endocrine feedback circuit, the liver–alpha cell axis, that may be disrupted by NAFLD. We investigated how NAFLD severity affects glucagon and insulin resistance in individuals with obesity and whether bariatric surgery improves these parameters. Plasma and liver biopsies from 33 individuals with obesity (collectively, OBE) were obtained before and 12 months after bariatric surgery (Roux‐en‐Y gastric bypass [RYGB] or sleeve gastrectomy [SG]). Nine healthy control individuals (collectively, CON) undergoing cholecystectomy were used as a comparison group. The NAFLD activity score (NAS) was used to subdivide study participants into the following groups: OBE‐no steatosis, OBE+steatosis, and nonalcoholic steatohepatitis (NASH) and/or grade 2 fibrosis (Fib) (OBE‐NASH‐Fib). Measurements of amino acids by targeted metabolomics and glucagon were performed. Glucagon, amino acids (P < 0.05), and the glucagon‐alanine index, a validated surrogate marker of glucagon resistance, were increased in OBE by 60%, 56%, and 61%, respectively, when compared with CON but irrespective of NAFLD severity. In contrast, markers of hepatic insulin resistance increased concomitantly with NAS. Hyperglucagonemia resolved in OBE‐no steatosis and OBE+steatosis but not in OBE‐NASH‐Fib (median, 7.0; interquartile range, 5.0‐9.8 pmol/L), regardless of improvement in insulin resistance and NAS. The type of surgery that participants underwent had no effect on metabolic outcomes. Conclusion: Glucagon resistance to amino acid metabolism exists in individuals with NAFLD independent of NAS severity. Patients with NASH showed persistent hyperglucagonemia 12 months after bariatric surgery, indicating that a disrupted liver–alpha cell may remain in NAFLD despite major improvement in liver histology. John Wiley and Sons Inc. 2020-09-01 /pmc/articles/PMC7603528/ /pubmed/33163832 http://dx.doi.org/10.1002/hep4.1562 Text en © 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Pedersen, Julie Steen
Rygg, Marte Opseth
Kristiansen, Viggo Bjerregaard
Olsen, Beth Hærstedt
Serizawa, Reza Rafiolsadat
Holst, Jens Juul
Madsbad, Sten
Gluud, Lise Lotte
Bendtsen, Flemming
Wewer Albrechtsen, Nicolai Jacob
Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
title Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
title_full Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
title_fullStr Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
title_full_unstemmed Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
title_short Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
title_sort nonalcoholic fatty liver disease impairs the liver–alpha cell axis independent of hepatic inflammation and fibrosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603528/
https://www.ncbi.nlm.nih.gov/pubmed/33163832
http://dx.doi.org/10.1002/hep4.1562
work_keys_str_mv AT pedersenjuliesteen nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT ryggmarteopseth nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT kristiansenviggobjerregaard nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT olsenbethhærstedt nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT serizawarezarafiolsadat nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT holstjensjuul nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT madsbadsten nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT gluudliselotte nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT bendtsenflemming nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis
AT weweralbrechtsennicolaijacob nonalcoholicfattyliverdiseaseimpairstheliveralphacellaxisindependentofhepaticinflammationandfibrosis